By Catherine Eckford (European Pharmaceutical Review)2024-01-18T12:15:51
Challenges such as market exclusivity and patient treatment preference are expected to shape the insomnia and Gaucher disease therapy landscape in the seven major markets (7MM) in 2032, research predicts.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-04-29T14:00:00Z 2026-04-29T15:00:00Z
Sponsored by USP
2026-05-27T14:00:00Z 2026-05-27T15:00:00Z
Sponsored by TA Instruments
2026-04-29T14:00:00 2026-04-29T15:00:00
Sponsored by USP
2025-09-19T15:46:00
Sponsored by ACCI, By European Pharmaceutical Review
2025-10-08T07:00:00
Sponsored by Entegris
2025-09-19T15:55:00
Sponsored by Sartorius, By Marko Narobe (Sartorius Biosepartions), Michael Gerrero (BridgeBio) and Srivatsan Ramesh (BridgeBio)
2025-05-30T09:22:00
Sponsored by Lonza QC Testing Solutions
Site powered by Webvision Cloud